Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

SARS-CoV-2-induced hypercytokinemia and inflammation are critically associated with COVID-19 severity. Baricitinib, a clinically approved JAK1/JAK2 inhibitor, is currently being investigated in COVID-19 clinical trials. Here, we investigated the immunologic and virologic efficacy of baricitinib in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoang, Timothy N., Pino, Maria, Boddapati, Arun K., Viox, Elise G., Starke, Carly E., Upadhyay, Amit A., Gumber, Sanjeev, Nekorchuk, Michael, Busman-Sahay, Kathleen, Strongin, Zachary, Harper, Justin L., Tharp, Gregory K., Pellegrini, Kathryn L., Kirejczyk, Shannon, Zandi, Keivan, Tao, Sijia, Horton, Tristan R., Beagle, Elizabeth N., Mahar, Ernestine A., Lee, Michelle Y.H., Cohen, Joyce, Jean, Sherrie M., Wood, Jennifer S., Connor-Stroud, Fawn, Stammen, Rachelle L., Delmas, Olivia M., Wang, Shelly, Cooney, Kimberly A., Sayegh, Michael N., Wang, Lanfang, Filev, Peter D., Weiskopf, Daniela, Silvestri, Guido, Waggoner, Jesse, Piantadosi, Anne, Kasturi, Sudhir P., Al-Shakhshir, Hilmi, Ribeiro, Susan P., Sekaly, Rafick P., Levit, Rebecca D., Estes, Jacob D., Vanderford, Thomas H., Schinazi, Raymond F., Bosinger, Steven E., Paiardini, Mirko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654323/
https://www.ncbi.nlm.nih.gov/pubmed/33278358
http://dx.doi.org/10.1016/j.cell.2020.11.007

Ejemplares similares

Ejemplares similares